ArticleInfection2026
Redefining susceptibility in practice : clinical and resistance outcomes of the EUCAST 'I' category for wild-type Pseudomonas aeruginosa.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2019 EUCAST redefinition of the "susceptible, increased exposure" (I) category aimed to optimize antimicrobial therapy and reduce unnecessary carbapenem prescribing. However, concerns remain that misinterpretation may promote carbapenem overuse. We evaluated clinical and resistance outcomes associated with I-category agents compared to meropenem in wild-type (WT) Pseudomonas aeruginosa infections.
methodsIn this retrospective cohort study, adult inpatients with microbiologically confirmed WT P. aeruginosa infections between January 2020 and March 2024 were included. Eligible isolates were susceptible to meropenem and categorized as "I" to at least one antipseudomonal agent (piperacillin-tazobactam, ceftazidime, cefepime, or ciprofloxacin). Patients received either I-category agents or meropenem as definitive therapy. Primary outcomes were clinical failure and all-cause mortality. Secondary outcomes included emergence of carbapenem-resistant microorganisms within one year.
resultsA total of 411 patients were included (I group n = 152; meropenem group n = 259). Clinical failure (9.2% vs. 6.9%, p = 0.409) and mortality at all time points were comparable between groups. However, meropenem use was independently associated with the development of carbapenem-resistant P. aeruginosa (CRPA) within one year (OR 2.38, 95% CI 1.02-5.57; p = 0.046). In contrast, emergence of any carbapenem-resistant organism was associated with prior antibiotic exposure and disease severity, but not treatment group.
conclusionIn WT P. aeruginosa infections, treatment with EUCAST I-category agents achieved clinical outcomes comparable to meropenem. However, meropenem use was independently associated with subsequent CRPA isolation. These findings support carbapenem-sparing strategies and highlight the long-term resistance implications of antimicrobial selection following the EUCAST redefinition.
Indexed as
Identifiers
42593638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.